Elranatamab
pfizer
['mmsm']
how do we deal with the evolving landscape of myeloma options. this is one of many potential pathways that could be considered. key points will be alternating targets, moas. great talk from cyrille touzeau. #mmsm #eha2023 
Haematologist @uclh, Associate Professor @ucl.  Chair UK Myeloma Research Alliance, NCRI Myeloma Group. All views are my own.